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Abstract
Background: This study investigates the effect of alendronate-treated osteoblasts, as well as the effect of low-level
laser therapy (LLLT) on the alendronate-treated osteoblasts. Bisphosphonate decreases the osteoblastic activity.
Various treatment modalities are used to enhance the bisphosphonate-treated osteoblasts; however, there were
no cell culture studies conducted using a low-level laser.
Methods: Human fetal osteoblastic (hFOB 1.19) cells were treated with 50 μM alendronate. Then, they were
irradiated with a 1.2 J/cm2 low-level Ga-Al-As laser (λ = 808 ± 3 nm, 80 mW, and 80 mA; spot size, 1 cm2; NDLux,
Seoul, Korea). The cell survivability was measured with the MTT assay. The three cytokines of osteoblasts, receptor
activator of nuclear factor κB ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor
(M-CSF) were analyzed.
Results: In the cells treated with alendronate at concentrations of 50 μM and higher, cell survivability significantly
decreased after 48 h (p < 0.05). After the applications of low-level laser on alendronate-treated cells, cell survivability
significantly increased at 72 h (p < 0.05). The expressions of OPG, RANKL, and M-CSF have decreased via the
alendronate. The RANKL and M-CSF expressions have increased, but the OPG was not significantly affected by
the LLLT.
Conclusions: The LLLT does not affect the OPG expression in the hFOB cell line, but it may increase the RANKL
and M-CSF expressions, thereby resulting in positive effects on osteoclastogenesis and bone remodeling.
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Background
Bisphosphonates (BPs) are a group of medications that are
known to be effective for inhibiting bone resorption. They
have been used in clinical settings for over 30 years [1] in
patients with multiple myeloma, metastatic skeletal disease,
and hypercalcemia of malignancy. BPs are also effective in
patients with Paget’s disease of bone and osteoporosis [2].
First described by Marx in 2003, bisphosphonate-related
osteonecrosis of the jaw (BRONJ) is a side effect of BP use
in dentistry [3]. Many authors have hypothesized that
BRONJ is related to the oversuppression of bone turnover
caused by BP usage [4]. Subramaian et al. [5] introduced a
hypothesis that focuses on a defective remodeling process
secondary to weakened synergism among the key cell
types that interact during bone remodeling, including
osteoblasts, osteoclasts, osteocytes, and bone lining cells.
At the cellular level, BPs have been known to act
directly or indirectly on the osteoclasts. Decreased oste-
oclastogenesis can occur either directly on osteoclast
precursors or indirectly by stimulating the osteoblasts to
produce an inhibitor of osteoclast formation. The inhib-
ition of the osteoblast-osteoclast pathway is an import-
ant component of the bisphosphonate activity [6].
The bone is continuously destroyed and reformed by a
strictly regulated equilibrium between osteoblastic bone
formation and osteoclastic resorption. During this process,
osteoblasts stimulate bone formation and mediate osteo-
clast differentiation and function via cell-to-cell contact
with osteoclast precursors. The roles of various substances
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related to the bone resorption process were recently
clarified. These substances include the receptor acti-
vator of nuclear factor κB ligand (RANKL), osteopro-
tegerin (OPG), and macrophage colony-stimulating
factor (M-CSF).
Researchers have focused on additional methods to
support healing in the management of BRONJ, including
medications and surgical procedures. An additional sup-
porting method is low-level laser therapy (LLLT) [7].
Yaakobi et al. [8] reported the curative effects of LLLT in
bone regeneration. In vitro laser biostimulation studies
have also been performed with osteoblasts or osteoblast-
like cells. Dörtbudak et al. [9] reported that LLLT has
stimulatory effects on the bone matrix formation in
osteoblast cell culture. However, the effects of LLLT on
bisphosphonate-treated osteoblasts are not well known.
This study investigated the expressions of RANKL,
OPG, and M-CSF in bisphosphonate-treated osteoblasts,
as well as the effects of LLLT on bisphosphonate-treated
osteoblasts, in order to provide an experimental basis
for BRONJ treatment.
Methods
Cell culture and treatment with alendronate
A human fetal osteoblast (hFOB 1.19) cell line was pur-
chased from the American Type Culture Collection
(ATCC; Rockville, MD, USA). The hFOB 1.19 cells were
cultured at 34 °C with 5% CO2 in an incubator. The
culture medium was a 1:1 mixture of Dulbecco/Vogt
modified Eagle’s minimal essential medium (DMEM)
and F12 (Invitrogen, USA) supplemented with 10%
fetal bovine serum (Invitrogen). Cells were cultured
on culture dishes and/or in several types of wells for
24 h, after which the original medium was removed
and the cells were washed with phosphate-buffered
saline (PBS). Alendronate (Sigma, St. Louis, MO, USA)
stock solution was added to the fresh medium in order to
attain drug concentrations of 0, 25, 50, 100, 250, 500, and
1000 μM.
Low-level laser irradiation
After the alendronate treatment, laser irradiation was
performed with a gallium-arsenide-aluminum (Ga-Al-
As) laser (λ = 808 ± 3 nm; 80 mW; 80 mA; spot size,
1 cm2; NDLux; Seoul, Korea) in the dark to eliminate
the influence of other light sources. Laser energy was
provided to the cells in continuous mode and vertical
direction of each well. The laser handpiece was fixed,
and the plate was moved to irradiate one well at a time
(5 cm above the bottom of the culture plate). Laser was
applied for a duration of 15 s for each well at 0, 24,
and 48 h. After 72 h, the total irradiated energy was
3.6 J/cm2.
Cell survivability assay
A total of 1 × 104 cells were seeded in a 96-well plate, in-
cubated for 24 h, and treated with alendronate at various
concentrations and time points with and without low-
level laser irradiation. Then, the cells were treated with
500 μg/ml of MTT stock solution and incubated at 34 °C
in a 5% CO2 atmosphere for 4 h. The medium was
aspirated, and the formazan crystals were dissolved in
DMSO. Cell survivability was monitored on an ELISA
reader (Tecan, Männedorf, Switzerland) at an excitation
emission wavelength of 570 nm.
Western blot analysis
The Western blot analysis was performed by using
mouse sRANKL, OPG, M-CSF, and rabbit polyclonal anti-
human GAPDH antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA).
The cells were washed twice with ice-cold PBS and
centrifuged at 2000 rpm for 10 min. The total cell
proteins were lysed with a RIPA buffer (300 mM
NaCl, 50 mM Tris-HCl [pH 7.6], 0.5% TritonX-100,
2 mM PMSF, 2 μg/ml aprotinin, and 2 μg/ml leupep-
tin) and incubated at 4 °C for 1 h. The lysates were
centrifuged at 14,000×g at 4 °C for 15 min, and so-
dium dodecyl sulfate (SDS) and sodium deoxycholic
acid (0.2% final concentration) were added. The pro-
tein concentrations of the cell lysates were deter-
mined by means of a Bradford protein assay (Bio-Rad,
Richmond, CA, USA), and the bovine serum albumin
(BSA) was used as the protein standard. A 20 μg pro-
tein sample from each well was separated and loaded
onto a 10% SDS-PAGE. The gels were transferred to
a PVDF (Amersham GE Healthcare, Little Chalfont,
UK), and they reacted to each antibody. Immuno-
staining with antibodies was performed by using a
Super Signal West Femto enhanced chemiluminescent
substrate and detected by Alpha Imager HP (Alpha
Innotech, Santa Clara, CA, USA). Equivalent protein
loading was confirmed by Ponceau S staining.
RNA isolation and real-time PCR
The hFOB cells were subjected to RNA extraction by
using spin columns (RNeasy; QIAGEN, Hilden,
Germany), according to the manufacturer’s instruc-
tions. RNA (2 μg) was reverse transcribed by using
the RevertAid First-Strand Synthesis System kit for
real-time polymerase chain reaction (Thermo Fisher
Scientific, Pittsburgh, PA, USA), according to the
manufacturer’s protocol. The cDNA was amplified
with the SYBR Green PCR master mix kit (Applied
Biosystems, Warrington, UK), and the PCR amplifica-
tion was performed by using the Chromo4 Real-Time
PCR Detection System (Bio-Rad Laboratories, Inc.).
Running conditions were as follows: incubation at
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95 °C for 3 min, and 40 cycles of incubation at 95 °C
for 15 s and 60 °C for 30 s. After the last cycle, the melting
curve analysis was performed at 55–95 °C intervals by
incremental temperature increases of 0.5 °C.
Detection of RANKL, OPG, and M-CSF by ELISA
The RANKL, OPG, and M-CSF secretions were mea-
sured with an ELISA kit (Quantikine, R&D Systems,
MN, USA), according to the manufacturer’s instruc-
tions. Cultured hFOB 1.19 cells were uniformly
seeded into 6-well culture dishes at a concentration
of 2 × 105 cells/well. When the cells became adherent
after 24 h, the medium was replaced with a medium
containing 50 μM alendronate for 48 h. Laser irradi-
ation was subsequently applied three times at 0, 24,
and 48 h. The supernatants were collected and ELISA
was used to determine the RANKL, OPG, and M-CSF
concentrations in each sample at 72 h. The values
were determined based on a standard curve set to
450 nm with a 540–570-nm wavelength correction
and expressed as pg/ml. All of the samples were sim-
ultaneously assayed.
Statistical analysis
A comparative analysis was run by one-way ANOVA
with Tukey’s post hoc test for cell survivability, RT-PCR,
and ELISA (SPSS version 17.0). The P values <0.05 were
considered as statistically significant.
Results
Cell survivability following the treatment with
alendronate and low-level laser therapy
An hFOB cell survivability assay was performed at 24,
48, and 72 h with 0, 25, 50, 100, 250, 500, and 1000 μM
alendronate concentrations (Fig. 1a). In the cells treated
with alendronate at concentrations of 50 μM and higher,
the cell survivability significantly decreased after 48 h
(p < 0.05). In order to evaluate the effects of LLLT on
alendronate-treated cells, the cell survivability was
measured at 24, 48, and 72 h after the laser applica-
tion (Fig. 1b).
The cell survivability in the alendronate-treated group
continuously decreased. After three applications of low-
level laser (LLL), the cell survivability significantly in-
creased at 72 h (p < 0.05).
Fig. 1 a Cell viability following treatment with different concentrations of alendronate and LLLT in hFOB 1.19 cells. b Cell viability following
treatment with 50 μM alendronate and LLLT in hFOB 1.19 cells. (*Statistical significance (p < 0.05) compared with alendronate-treated group)
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Effects of alendronate and LLLT on OPG expression
Western blot, RT-PCR, and ELISA were used in order to
determine the OPG expression. The OPG expression in
the alendronate-treated cells decreased more than that
of the control group; however, there was no statistical
significance (Fig. 2b). In the alendronate cells treated
with the laser, the OPG expression increased more than
that of the alendronate-treated group; however, the dif-
ference was not statistically significant (Fig. 2b, c).
Effects of alendronate and LLLT on RANKL expression
Western blot, RT-PCR, and ELISA were used in order to
determine the RANKL expression, which induces osteo-
clastogenesis. In the alendronate-treated cells, the RANKL
expression decreased more than that of the control group
(Fig. 3b). In the alendronate cells treated with the laser,
the RANKL expression increased more than that of the
alendronate-treated group (Fig. 3b, c).
Effects of alendronate and LLLT on M-CSF expression
Western blot, RT-PCR, and ELISA were performed in
order to investigate the M-CSF expression, which is
another factor related to osteoclastogenesis. In the cells
treated with alendronate, the M-CSF expression de-
creased more than that of the control group; however,
there was no statistical significance (Fig. 4b). In the alen-
dronate cells treated with the laser, the M-CSF expres-
sion increased more than that of the alendronate-treated
group (Fig. 4b, c).
Discussion
BPs are the most widely used anti-resorptive drugs for
metabolic bone diseases [10]. BPs are pyrophosphate-
like structures with two variable regions (R1 and R2) on
the carbon atom of the BP molecule attached to the
basic P-C-P structure. This allows for variations in the
molecular structure and a range of corresponding poten-
cies. BPs are classified according to the chemical group
added to the base pyrophosphoric nucleus at the R2 side
chain. Alkyl derivatives are the first generation of
drugs (e.g., etidronate). The second generation includes
Fig. 2 OPG expression in cells treated with alendronate and LLLT.
a Western blot. b RT-PCR. c ELISA
Fig. 3 RANKL expression in cells treated with alendronate and LLLT.
a Western blot. b RT-PCR. c ELISA
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amino-bisphosphonates with a terminal amino group (e.g.,
alendronate and pamidronate), while the third generation
is characterized by a cyclic side chain (e.g., zoledronate).
Depending on whether or not nitrogen is attached to the
R2 side chain, BPs are classified as nitrogen-containing
BPs (NBPs) or non-nitrogen-containing BPs (NNBPs).
NBPs (e.g., pamidronate, alendronate, risedronate, iban-
dronate, and zoledronate) inhibit farnesyl pyrophosphate
synthase (FPPS), which is an enzyme in the mevalonate
pathway, and block the prenylation of small GTPase-
signaling proteins. This results in the accumulation of
active unprenylated GTPases in the cytoplasm of the
osteoclast, which causes an inappropriate activation of the
downstream signaling pathways, thereby leading to the
disruption of normal osteoclast function and survival. As
a result, NBPs suppress bone resorption through a direct
effect on the osteoclasts and their precursors [11, 12].
In the present study, we examined the effects of alen-
dronate on osteoblasts. Alendronate is the most widely
prescribed oral BP, which is more likely to cause BRONJ.
However, the precise mechanism of alendronate in
BRONJ remains elusive [13].
The effects of BPs on osteoclasts are well understood,
and their toxicity effects on osteoclast are thought to
influence the onset of BRONJ. Besides the inhibition of
osteoclasts, many complicated events may be related to
BRONJ development, and interactions among the bone
cells must be considered as a whole [14]. Although the
majority of in vitro BP studies have focused on the activ-
ities of the osteoclast lineage cells, recent studies have
suggested that the presence of osteoblastic family cells is
required in order for the anti-resorptive effects of BPs to
occur. This effect may depend upon soluble factors that
are secreted by the osteoblasts, which inhibit the forma-
tion and activity of the osteoclasts [15]. RANKL, OPG,
and M-CSF are essential factors that are produced by
the osteoblast/stromal cells for osteoclast-osteoblast in-
teractions. RANKL is an important factor in protecting
bone resorption, extending the life of osteoclasts, and
promoting differentiation. OPG is known as a decoy
receptor protein that prohibits osteoclast activation by
protecting the function of the receptor activator nuclear
factor-kB (RANK), which is involved in osteoclast differ-
entiation by combining with RANKL [16]. The role of
OPG is largely associated with an initiation phase, in
which OPG counteracts the osteoclastogenic activity of
RANKL. During bone formation, osteoclast differenti-
ation is suppressed through the OPG that is produced
by the osteoblast [17]. Osteoblasts produce M-CSF,
which is required for cell survival in the macrophage-
osteoclast lineage, and the control of cell migration and
reorganization [18]. However, studies on the effects of
BPs on osteoblasts are the subject of debate. In addition,
the effects of BPs on osteoblastic activities have been
sparsely investigated in terms of BRONJ development
[19–21]. Knowledge regarding the effects of alendronate
on the hFOB cells, particularly in the OPG/RANKL
system, is lacking.
In order to address this data gap, we investigated the
expressions of RANKL, OPG, and M-CSF in BP-treated
hFOB cells. In the cells treated with alendronate at con-
centrations of 50 μM and higher, the cell survivability
significantly decreased after 48 h, and there was a
strongly negative dose-dependent influence on the via-
bility of the osteoblasts and induced toxic effects in the
hFOB cells. Enjuanes et al. [12] reported that high con-
centrations of alendronate inhibited osteoblast prolifera-
tion in the primary hFOB cells and indicated that the
drug did not significantly inhibit proliferative effects, as
compared to controls at lower concentrations (≤10–
5 M). Naidu et al. [22] reported that high concentrations
of alendronate and zoledronate were cytotoxic and de-
creased the cell survivability at 72 h, and cytotoxicity
leading to cell death was likely to result in osteonecrosis.
Our results are similar to these studies and suggest that
alendronate at higher concentrations, more than 50 μM
Fig. 4 M-CSF expression in cells treated with alendronate and LLLT.
a Western blot. b RT-PCR. c ELISA
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will affect hFOB cell proliferation and viability signifi-
cantly after 48 h. We observed that 50 μM alendronate
appeared to suppress M-CSF and RANKL expressions,
and decreased the OPG expression, as compared to the
control group. The RANKL expression appeared to be
more suppressed than the OPG expression. RANKL ex-
pression level was more decreased than OPG or M-CSF
in RT-PCR and ELISA result. Appeared by Western blot
analysis, OPG, RNAKL, and M-CSF proteins were de-
creased in alendronate-treated cells.
Therefore, we proposed that the BPs interfere with os-
teoclastogenesis through regulating mediators (e.g., M-
CSF, RANKL, and OPG) by inhibition of their expres-
sions. However, Lin et al. [23] found no significant influ-
ence on osteoblast RANKL and OPG gene expressions
during a 48-h experimental period when investigating
alendronate and pamidronate. In contrast, Mackie et al.
[24] reported that the RANKL gene expression was
inhibited, while the OPG gene expression was not
altered by stimulation with pamidronate in an osteosar-
coma cell line for 6 days. Although the reasons for these
differences have not been completely explained, the dis-
tinct effects of various BPs (e.g., pamidronate, zoledro-
nate, and alendronate) and the use of different cell lines
(e.g., human vs. rat and primary vs. cancer) could play a
role [25]. Additional in-depth studies will be required in
order to understand the reasons for these differences.
In medicine and dentistry, diode lasers have been used
predominantly in applications that are broadly termed as
LLLT or biostimulation [26], and many studies have
evaluated the therapeutic effects of LLLT on a broad
range of disorders. LLLT applications, which have been
promoted by some authors and manufacturers of the
LLLT devices, included the acceleration of wound heal-
ing, enhancement of the remodeling and repair of bones,
restoration of normal neural function following injury,
pain attenuation, and modulation of the immune system
[27]. Recently, research on the use of LLLs in dentistry
has proceeded gradually, and the range of clinical appli-
cations has been extended. The term LLL includes soft
lasers, mid-lasers, low-energy lasers, and cold lasers. A
new international definition considers LLLT to be laser
therapies that do not increase tissue temperature over
36.5 °C or normal body temperature. The wavelength of
such lasers is reported to be 500–1200 nm. Recent liter-
atures regarding pre-osteoblast stimulation with red
laser were reported [28–31]. We used a Ga–As–Al laser
with a wavelength of 808 nm, which is within the
prescribed range. It is still unclear as to which of the pa-
rameters has the greatest effect on therapeutic efficacy,
even though there are information about total energy
dose, energy density, and laser spectrum. In this study,
the greatest biostimulatory effect was observed when a
dose of 3.6 J/cm2 was used. This may be due to the use
of different methodologies, such as different types of
cells, experimental timings, and radiation distance.
Many previous studies have demonstrated that LLLT
is optimal in tissues under a specific stress, such as hyp-
oxia [32–34], diabetes [35–38], and nutritional deficit
[39]. Other previous studies have shown that LLLT may
enhance the osteogenic potential of osteoblasts, and may
promote metabolic bone activity and bone remodeling
[40, 41]. LLLT has recently been used as a supportive
technique in BRONJ treatment. Clinical cases that de-
scribe the application of LLLT to treat BRONJ have
been reported, based on in vivo and in vitro expe-
rimental studies that demonstrated a biostimulative
effect [7, 42, 43].
Vescovi et al. [44] reported successful results by using
a combined treatment in BRONJ patients with medica-
tion plus Er:YAG laser surgery and LLLT. However,
there have been no cell culture studies designed to ex-
plain the positive results obtained with the LLLT bio-
stimulation in combination with surgery in clinical
BRONJ cases. The present study investigated the effects
of LLLT in hFOB cells treated with alendronate. The cell
survivability significantly increased at 72 h relative to the
alendronate-treated cells after LLT application. More-
over, we observed a significant increase in RANKL and
M-CSF expressions, as compared to the cells treated
only with alendronate. The results showed that alendro-
nate at a concentration of 50 μM appeared to inhibit
hFOB cell survivability, and suppress the M-CSF and
RANKL expressions, and decreased the OPG expression,
as compared to the control group. Moreover, the LLLT
increased the RANKL and M-CSF expressions relative
to the alendronate-treated cells.
In this study, the greatest biostimulatory effect was
observed when a dose of 3.6 J/cm2 was used. It may be
due to the use of different methodologies, such as differ-
ent types of cells, experimental timings, and radiation
distance. Recently, the choice for an appropriate laser
source and standardization of radiation parameters will
require further research in order to obtain an optimal
result for a low-level laser study.
Conclusions
The present study was conducted in order to determine
if LLLT influences cell survivability and cellular func-
tions in hFOB cells following alendronate exposure. The
results showed that alendronate at concentrations of
50 μM and higher inhibited hFOB cell survivability.
Alendronate at a concentration of 50 μM appeared to
suppress the M-CSF and RANKL expressions, and de-
creased the OPG expression, as compared to the control
group. Moreover, LLLT increased the RANKL and
M-CSF expressions relative to the alendronate-
treated cells, thereby resulting in positive effects on
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osteoclastogenesis. These results demonstrated the
possibility of LLLT in partially overcoming the inhibitory
effects of BP and provide an experimental basis to explain
the clinical effects of LLLT as a potential treatment modal-
ity for BRONJ.
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